報價延遲最少15分鐘:2025/07/09 01:11 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.1 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-325.05/-289.80
|
|
企業價值
12.94M
|
| 資產負債 |
|
每股賬面淨值
-0.51
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/09 01:11 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells. |